#United States #New York #cGvHD #Graviton Bioscience #GV101

Graviton BioScience's Promising Phase IIB Results for GV101 in Chronic Graft versus Host Disease

Graviton BioScience Corporation recently announced the successful publication of clinical trial findings related to its innovative therapy, GV101, a selective ROCK2 inhibitor, designed to treat chronic graft versus host disease (cGvHD). The data, published in the peer-reviewed journal Signal Transduction and Targeted Therapy, highlights the therapeutic potential of this novel treatment for patients who have not responded well to conventional therapies.

Overview of the Study

The Phase Ib clinical trial was conducted across multiple centers and aimed at understanding the safety, tolerability, and efficacy of GV101 in patients with moderate to severe cGvHD. Out of the 60 enrolled participants, half received a dose of 200 mg, while the other half was treated with 400 mg. All participants had previously undergone one to five systemic therapies without adequate responses. The findings indicated a remarkable best overall response rate (bORR) of 86.2% for the 400 mg group and 67.9% for the 200 mg group, assessed at 24 weeks.

This study is particularly significant as it demonstrates that GV101 not only surpassed the six-month bORRs from existing approved treatments for steroid-refractory cGvHD but it also exhibited a favorable safety profile. Importantly, failure-free survival (FFS) was recorded at 83.9% and reached 89.4% for the higher dosage, suggesting strong therapeutic advantages in this patient population.

Efficacy Highlights

Analyzing GV101's efficacy, the trial found that complete responses occurred across various organ systems, with only one participant having lower gastrointestinal involvement. Additionally, notable organ response rates were observed, including 52.6% for the liver, 50.0% for the esophagus, and 50.0% for the upper gastrointestinal tract. These metrics portray GV101 as a potent option for addressing the serious manifestations of cGvHD.

Key Findings:

• - bORR: 86.2% (400 mg), 67.9% (200 mg)
• - FFS: 89.4% (400 mg), 78.6% (200 mg)
• - OS: 96.6% (400 mg), 100% (200 mg)
• - Complete Response: All but one organ system

Safety Profile

Safety analyses indicated a strong profile for GV101, with only mild adverse events reported. The most common event was a transient elevation in bilirubin levels (81.7%), which was attributed to the inhibition mechanism of the drug and not linked to serious complications such as infections or significant liver enzyme elevation. Furthermore, the trial did not observe any severe hematological toxicities, which are common in many cancer therapies.

Notably, only one serious adverse event occurred, categorized as grade ≥3, which involved benign bilirubin elevation. The team at Graviton remains optimistic, as they plan to advance GV101 into Phase III randomized controlled trials, further establishing its efficacy and safety in the treatment landscape of cGvHD.

Understanding cGvHD

Chronic graft versus host disease affects many patients post-allogeneic stem cell transplantation, with about 18,700 cases in the U.S. and an estimated 53,000 new cases globally each year. The complication arises when donor immune cells attack the recipient's healthy tissues, resulting in inflammation and potential organ damage. Many current treatments fail to deliver satisfactory results, creating an urgent need for effective, novel therapeutic approaches that can adequately address both symptoms and the underlying mechanisms of cGvHD.

About GV101 and Graviton BioScience

GV101 stands out as a clinical-stage, best-in-class selective inhibitor targeting the ROCK2 pathways, which play critical roles in inflammatory and fibrotic responses. Graviton BioScience, a clinical-stage biotechnology company, is committed to developing innovative pharmacological therapies to address various serious medical conditions, including those related to metabolism and central nervous system disorders. Led by Dr. Samuel Waksal, the organization continues to expand its portfolio of selective ROCK2 inhibitors and other groundbreaking therapeutics tailored for patients suffering from autoimmune and fibrotic conditions.

As the data unfold, the medical community watches in anticipation for upcoming developments surrounding GV101 and its possible impact on improving lives affected by chronic graft versus host disease.